In mice with pulmonary fibrosis, tail-intravenous injection of miR-29a agomir would result in a significant reduction in TGF-β1 and CTGF content, the severity of pulmonary fibrosis, as well as the suppression of Smad3 expression in the nucleus (Yun and Wang, 2024). This evidence concerns the gene CCN2 and pulmonary fibrosis.